BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12224977)

  • 1. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
    Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
    J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
    Geisse JK; Rich P; Pandya A; Gross K; Andres K; Ginkel A; Owens M
    J Am Acad Dermatol; 2002 Sep; 47(3):390-8. PubMed ID: 12196749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
    Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
    J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.
    Prokosch V; Thanos S; Spaniol K; Stupp T
    Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):121-5. PubMed ID: 20886224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma.
    Torres A; Niemeyer A; Berkes B; Marra D; Schanbacher C; González S; Owens M; Morgan B
    Dermatol Surg; 2004 Dec; 30(12 Pt 1):1462-9. PubMed ID: 15606733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.
    Eigentler TK; Kamin A; Weide BM; Breuninger H; Caroli UM; Möhrle M; Radny P; Garbe C
    J Am Acad Dermatol; 2007 Oct; 57(4):616-21. PubMed ID: 17610993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
    Vun Y; Siller G
    Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma.
    Ezughah FI; Dawe RS; Ibbotson SH; Fleming CJ
    J Dermatolog Treat; 2008; 19(2):111-7. PubMed ID: 17917935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.
    Beutner KR; Geisse JK; Helman D; Fox TL; Ginkel A; Owens ML
    J Am Acad Dermatol; 1999 Dec; 41(6):1002-7. PubMed ID: 10570388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
    Tillman DK; Carroll MT
    Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.